what this node claims
AlphaFold metrics / GRIN2B
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
49%
low debt pressure
24%
61%structureusable
pLDDT 60.7
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- low
- confidence pct
- 60.7
- coverage context
- missing or not linked
- interpretation
- weak structural context; downstream claims should be conservative
- pae context
- missing or not linked
- plddt avg
- 60.7
- sequence length
- 0
AlphaFold metrics visual
Low-confidence regions present
1484 residues / min 24.03 / max 96.0 / source alphafold db
Very high
17.8%
264 residues / >=90
Confident
29.2%
434 residues / 70-89
Low
8.8%
131 residues / 50-69
Very low
44.1%
655 residues / <50
weak structural context; downstream claims should be conservative
Near-complete coverage / observed 1484 of 1484 residues.
- residues 845-1484 / mean 33.4
- residues 1-32 / mean 42.87
- residues 581-600 / mean 52.73
- residues 44-58 / mean 60.07
proof debt register
24%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.